Cancer Supportive Care Drugs Market Expected to Reach $25 Billion by 2032—Allied Market Research

According to a new report published by Allied Market Research, titled, “Cancer Supportive Care Drugs Market," The cancer supportive care drugs market was valued at $20.4 billion in 2022, and is estimated to reach $25 billion by 2032, growing at a CAGR of 2% from 2023 to 2032.

 The growth of the cancer supportive care drugs market is significantly driven by increasing government initiatives aimed at enhancing cancer care. For instance, in May 2020, the federal government announced that it would be investing $150 million over five years in the Canadian Partnership against cancer. This investment focuses on improving access to cancer care and supporting patients, highlighting the commitment to advancing comprehensive cancer care. Such government initiatives play a pivotal role in bolstering the market by fostering innovation, research, and infrastructure development and are also the cancer supportive care drugs market trends.

Furthermore, the rise in biosimilar adoption holds promise for cost-effective alternatives to biologic therapies, fostering competition and potentially reducing healthcare expenses. Regulatory approvals signal a conducive environment for innovation and market expansion and are also the upcoming cancer supportive care drugs market opportunity. For instance, in June 2021, Lupin Limited, an innovation-led transnational pharmaceutical company, announced that the U.S. FDA has accepted the Biologics License Application (BLA) for its proposed biosimilar to Neulasta (pegfilgrastim) through a filing using the 351(k) pathway. As pharmaceutical companies continue to navigate regulatory pathways, the cancer supportive care drugs market benefits from an expanding portfolio of approved biosimilars, providing clinicians and patients with enhanced choices and contributing to the overall growth and accessibility of cancer care. 

However, advancements in targeted therapy for cancer, coupled with a shift towards more personalized and precise treatments, restrain the cancer supportive care drugs market. Targeted therapies often result in fewer adverse effects, reducing the demand for supportive care drugs that traditionally address broader treatment-related side effects. 

On the basis of type, the cancer supportive care drugs market analysis is segmented into erythropoiesis-stimulating agents (ESA), granulocyte colony-stimulating factors (G-CSFs), antiemetics, bisphosphonates, opioids, NSAIDs (non-steroidal anti-inflammatory drugs), and others. The granulocyte colony-stimulating factors (G-CSFs) segment accounted for the largest cancer supportive care drugs market size in terms of revenue in 2022 and is expected to maintain its lead during the forecast period. G-CSFs play a crucial role in supporting cancer patients by stimulating the production of white blood cells, thereby aiding in the prevention of infections during chemotherapy. This vital function has positioned G-CSFs as a primary choice in cancer supportive care, driving their market share and revenue to the forefront.  

However, the antiemetics segment is expected to register the fastest CAGR in the forecast period. Antiemetics significantly enhance the quality of life for patients undergoing chemotherapy. The rising demand for effective nausea and vomiting control is expected to drive the rapid growth of the antiemetics segment in the cancer supportive care drugs market forecast. 
 
On the basis of application, the market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, liver cancer, stomach cancer and others. The breast cancer segment accounted for the largest cancer supportive care drugs market share in terms of revenue in 2022 and is expected to maintain its lead during the forecast period. The surge in breast cancer prevalence and increased adoption of diverse treatments, often accompanied by side effects, contribute to a rising demand for cancer support care drugs. This sustained need positions the breast cancer segment as a significant driver of market revenue and is also cancer supportive care drugs market growth.  

However, the lung cancer segment is expected to register the fastest CAGR in the forecast period. The escalating prevalence of lung cancer and the increased adoption of diverse treatments have led to a surge in lung cancer cases, intensifying the demand for supportive care interventions. As awareness about the importance of comprehensive and effective supportive care grows and treatment options expand, there is an imperative need to address the unique challenges associated with lung cancer. This drive is essential for enhancing the overall quality of life for individuals affected by lung cancer, emphasizing the critical role of supportive care in managing the complexities of the disease and its treatments. 

On the basis of distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. The drug stores & retail pharmacies segment accounted for the largest cancer supportive care drugs market share in terms of revenue in 2022 and is expected to maintain its lead during the forecast period owing to several factors, including convenience, accessibility, and the widespread presence of drug stores and retail pharmacies. Additionally, the familiarity of patients with these establishments, along with the availability of over-the-counter supportive care products, contributes to the segment's revenue dominance. 

However, the online providers segment is expected to exhibit the fastest CAGR during the forecast period. This is primarily due to the convenience, accessibility, and ability to reach a broader audience through digital channels. In addition, advancements in e-commerce and telehealth technologies further drive the online providers' significance in the cancer supportive care drugs market, making them a dynamic and evolving aspect of the healthcare landscape.  

On the basis of region, North America had the largest cancer supportive care drugs market size in terms of revenue in 2022 and is expected to maintain its lead during the forecast period owing to several factors. The robust market position is attributed to the well-established healthcare infrastructure, high cancer incidence, advanced treatment accessibility, and a strong focus on improving patient outcomes in the region. However, Asia-Pacific is expected to exhibit the fastest growth during the forecast period, owing to large population base, increase in healthcare awareness, and rise in incidences of cancer cases contribute to a growing demand for cancer supportive care drugs in this region.  

Key findings of the study 

• On the basis of type, the granulocyte colony-stimulating factors (G-CSFs) segment dominated the  cancer supportive care drugs industry in terms of revenue in 2022. However, the antiemetics segment is anticipated to grow at the fastest CAGR during the forecast period. 
• On the basis of type, the breast cancer segment dominated the cancer supportive care drugs industry in terms of revenue in 2022. However, the lung cancer segment is anticipated to grow at the fastest CAGR during the forecast period. 
• On the basis of distribution channel, the drug stores and retail pharmacies segment dominated the market in terms of revenue in 2022. However, the online providers segment is anticipated to grow at the fastest CAGR during the forecast period. 
• Region wise, North America generated the largest revenue in 2022. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.